Skip to main content

Table 2 Changes in the number of pigs developing fever in various treatment groups over time after classical swine fever virus (CSFV) challengea.

From: Porcine circovirus type 2 (PCV2) infection decreases the efficacy of an attenuated classical swine fever virus (CSFV) vaccine

dpi

27

30

33

36

39

42

45

Group 1

0/6b

0/6

1/6

1/6

1/6

0/6

0/6

Group 2

0/6

6/6

3/6

4/6

3/4

0/1

0/0

Group 3

0/3

0/3

0/3

0/3

0/3

0/3

0/3

Group 4

0/3

1/3

2/3

2/3

2/3

1/3

0/0

  1. Group 1: PCV2-infected/LPC-vaccinated/CSFV-challenged; group 2: PCV2-infected/CSFV-challenged; group 3: LPC-vaccinated/CSFV-challenged, and group 4: CSFV-challenged.
  2. aThe pigs were inoculated with 105.3 TCID50 of PCV2 (group 1 and 2), 1 dose of LPC vaccine (group 1 and 3), and 106.8 TCID50 of wild-type CSFV (ALD) (group 1, 2, 3, and 4) at 0, 12, and 27 dpi, respectively.
  3. bNumber of animals with fever/number of surviving animals.